Scientific deep-dive

GLORY-2: How Much Weight Did Mazdutide 9 mg Produce?

In the phase 3 GLORY-2 trial, mazdutide 9 mg produced a mean weight change of −16.65% at 60 weeks versus −1.50% on placebo in Chinese adults with obesity. Here is why earlier reports said 18.55% or 20.1%, and how often vomiting and nausea occurred.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
7 min read·12 citations

Mazdutide 9 mg produced a mean weight change of −16.65% at 60 weeks in GLORY-2, against −1.50% on placebo, a between-group difference of −15.15 percentage points in Chinese adults with a BMI of 30 or higher [1]. That is the peer-reviewed figure from JAMA. The larger numbers that circulated first, 18.55% and “up to 20.1%,” came from the manufacturer’s November 2025 release [2], and the trial tested a younger, entirely Chinese population, so neither figure transfers directly to US patients.

How GLORY-2 was designed

GLORY-2 was a double-blind, placebo-controlled phase 3 trial run at 27 hospitals in China from December 2023 to November 2025 [1]. Adults with a BMI of at least 30, with or without type 2 diabetes, were randomized 2:1 to once-weekly subcutaneous mazdutide 9 mg (n = 308) or placebo (n = 154), on top of a reduced-calorie diet and increased physical activity [1]. There were two coprimary outcomes, both at week 60: percentage weight change and the share of people losing at least 5% [1].

The 461 people who received treatment were relatively young, with a mean age of 33.9 years, compared with 47.7 years in the US phase 2 trial described below [1][6]. In GLORY-2, 64.0% were female, mean weight was 94.0 kg, mean BMI was 34.3, and 16.1% had type 2 diabetes [1]. The trial registry lists a 12-week off-drug follow-up after the 60 weeks of treatment [10], but the abstract does not report what happened to weight during that period. Readers should not assume the result held after stopping.

Innovent Biologics, which develops mazdutide in China, sponsored the registered trial [10], and several of the paper’s authors list Innovent as their affiliation [1].

What the trial found at week 60

  • Average weight change: −16.65% (95% CI, −18.19% to −15.12%) with mazdutide versus −1.50% (95% CI, −3.43% to 0.43%) with placebo [1].
  • Between-group difference: −15.15 percentage points (95% CI, −17.22 to −13.09; P < .001) [1].
  • At least 5% weight loss: 84.3% on mazdutide versus 33.1% on placebo [1]. A third of the placebo group reaching that mark suggests diet and activity support contributed in both arms.

The authors called this “clinically meaningful weight reduction” in adults with moderate to severe obesity, and in the same sentence noted the gastrointestinal reactions that came with it [1].

Why you may have seen 18.55% or 20.1%

Innovent’s November 2025 topline release reported a mean weight reduction of 18.55% on mazdutide 9 mg versus 3.02% on placebo at week 60, with 44.0% versus 2.6% losing at least 20% [2]. Its headline figure, 20.08%, applied only to participants without type 2 diabetes, whose placebo comparison was 2.81% [2]. In that same subgroup, 48.7% lost at least 20%, versus 3.1% on placebo [2].

The release does not name the statistical approach behind those figures, and the JAMA abstract does not name an estimand either. It says only that the analyses covered participants who received at least 1 dose [1]. So the cause of the gap cannot be settled from these two documents. One detail helps: both arms moved. The release’s arms differ by about 15.5 points (18.55 minus 3.02), close to the 15.15-point difference in JAMA [1][2]. The drug’s effect over placebo looks similar in the two reports, while the absolute number shifts.

The non-diabetes subgroup and a liver-fat result (−71.9% versus 5.1% in a subset without diabetes whose baseline liver fat was at least 10%) come from the company release [2] and do not appear in the JAMA abstract. Treat them as sponsor-reported until you can check them against the paper.

Side effects at the higher dose

Vomiting was the most common adverse event, at 53.1% with mazdutide versus 1.3% with placebo, followed by nausea (46.9% vs 3.2%) and diarrhea (39.4% vs 6.5%) [1]. Most events were mild to moderate [1]. Even so, more than half of treated participants vomiting at least once is a substantial burden to raise with anyone considering the dose. Few people left treatment over adverse events: 2.9% stopped, against 0% on placebo [1].

The abstract does not describe the dose-escalation schedule or how long the gastrointestinal effects lasted. The registry says only that doses were “gradually increased” [10], so a claim about how quickly these symptoms settle would go beyond what the abstract supports. In the smaller 24-week phase 2 trial of the same dose, nausea affected 50.0%, diarrhea 38.3%, and vomiting 36.7% of the mazdutide group [5].

Where 9 mg sits in the mazdutide dose ladder

The table sets the published trials side by side for orientation. Duration, population, and analysis method all differ, so the rows should not be ranked as if they came from one experiment. GLORY-1 is reported in its NEJM abstract [4], the Chinese 9 mg phase 2 trial in Med [5], and the US phase 2 trial in Lancet Diabetes & Endocrinology [6]. The first row repeats GLORY-2 [1].

Mazdutide trial results by dose. Cross-trial orientation only, not a head-to-head comparison.
TrialPopulationDoseTimepointWeight change vs placeboAnalysis named in abstract
GLORY-2, phase 3China, BMI ≥30, 16.1% with type 2 diabetes9 mgWeek 60−16.65% vs −1.50%Participants with at least 1 dose; no estimand named
GLORY-1, phase 3China, BMI ≥28, or 24 to <28 with a weight-related condition4 mg; 6 mgWeek 48−11.00%; −14.01% vs 0.30%Treatment-policy, stated for the week 32 primary end points
Chinese phase 2China, BMI ≥30, no diabetes, n = 809 mgWeek 24−12.78% vs 1.80%None named
US phase 2 (Eli Lilly)US, BMI ≥30, or 27 to <30 with a comorbidity, no type 2 diabetes10 mg; 16 mgWeek 32−15.6%; −18.1% vs −0.9%Efficacy (hypothetical)

The US trial matters for a different reason than its headline. It offers dose-range evidence from outside China, randomizing 179 adults with a mean age of 47.7 years to placebo or mazdutide up to 16 mg [6]. Eli Lilly funded it, and its primary result uses an efficacy estimand, which estimates the effect had people stayed on treatment as planned [6]. It also shows a tolerability ceiling: 20% of the 16 mg group stopped treatment because of adverse events, mainly gastrointestinal ones [6]. The trial did not test 9 mg, and that 20% cannot be compared directly with GLORY-2’s 2.9%, given the different doses, countries, and trial conduct.

For background on the drug itself, including how the glucagon receptor differs from semaglutide’s target, see what mazdutide is and where it is approved. The earlier trials, including its type 2 diabetes program, are covered in our wider mazdutide evidence review.

How it compares with Wegovy and Zepbound

No head-to-head results for mazdutide 9 mg against semaglutide 2.4 mg or tirzepatide appear in the sources reviewed for this article, so any comparison is indirect. A phase 3 trial against semaglutide, GLORY-3, is registered, with mazdutide titrated to 9 mg, but it enrolled Chinese adults with overweight or obesity and fatty liver disease [2][12]. The closest available tool is a 2026 BMJ network meta-analysis of 262 trials, which estimated one-year weight loss relative to lifestyle modification alone [7]. It put tirzepatide at −14.9% and subcutaneous semaglutide at −9.8%, with moderate to high certainty. Ecnoglutide, mazdutide, and retatrutide were grouped as emerging agents at 13.1% to 14.6%, with very low to low certainty [7]. Its literature search ended on 12 November 2025 [7], before the JAMA report of GLORY-2 appeared, and the abstract does not specify a mazdutide dose.

A separate 2026 meta-analysis of nine mazdutide trials reached a similar caution about the non-diabetes evidence at 3, 4, and 6 mg: differences from placebo of −6.56%, −9.92%, and −11.1%, rated very low certainty because of heterogeneity and few trials [8]. Its authors asked for longer, multi-ethnic studies on durability, generalizability, and cardiovascular safety [8]. Survodutide, which targets the same two receptors, faces the same kind of cross-trial limits.

Regulatory status and what to ask a prescriber

China approved mazdutide in June 2025 for long-term weight management and in September 2025 for glycemic control in type 2 diabetes [9]. In a November 2025 release, Innovent said China’s regulator had accepted a supplementary application for the 9 mg dose in moderate to severe obesity, based on GLORY-2 [3]. A company statement that an application was accepted for review is not an approval. As of November 2026, mazdutide had no FDA approval, and the US trial reported here is phase 2 [6].

Innovent has also registered a study of a still higher 15 mg dose in Chinese patients with moderate to severe obesity [11]. Its title describes tolerance and pharmacokinetics, so it should not be read as an efficacy trial.

Anyone reading about GLORY-2 while weighing treatment could ask a prescriber which approved options fit their BMI, diabetes status, and history with gastrointestinal side effects. It is also fair to ask how the evidence for those drugs compares in people like them. If a seller offers mazdutide in the US by pointing to these results, a prescriber or pharmacist can help check what the product is and whether it can be legally dispensed.

Frequently Asked Questions

In the phase 3 GLORY-2 trial published in JAMA, mean weight change at week 60 was −16.65% on mazdutide 9 mg and −1.50% on placebo in Chinese adults with a BMI of 30 or higher. The difference between groups was −15.15 percentage points. In the mazdutide group, 84.3% lost at least 5%, compared with 33.1% on placebo.
Those figures come from the manufacturer's November 2025 release, which reported 18.55% overall and 20.08% among participants without type 2 diabetes. The JAMA abstract reports −16.65% overall. The release and the abstract do not name the statistical approach behind their figures, so the exact reason for the gap cannot be determined from those two documents.
In GLORY-2 the most common adverse events were vomiting (53.1% vs 1.3% on placebo), nausea (46.9% vs 3.2%), and diarrhea (39.4% vs 6.5%). Most were mild to moderate, and 2.9% of people on mazdutide stopped treatment because of adverse events, compared with 0% on placebo.
As of November 2026 it had no FDA approval, and the US trial reported here is phase 2. China approved the drug in 2025, and in November 2025 the manufacturer said a supplementary application for the 9 mg dose had been accepted for review there. A prescriber can discuss approved alternatives.

References

  1. 1.Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, et al.; GLORY-2 Trial Investigators. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42251595.
  2. 2.Innovent Biologics. Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints (press release, November 19, 2025). BioSpace. 2025. https://www.biospace.com/press-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints
  3. 3.Innovent Biologics. Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA (press release, November 25, 2025). PR Newswire. 2025. https://www.prnewswire.com/news-releases/mazdutide-9mg-supplementary-application-accepted-for-review-by-chinas-nmpa-potentially-offering-a-novel-drug-option-for-moderate-to-severe-obese-population-302625421.html
  4. 4.Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. PMID: 40421736.
  5. 5.Ji L, Jiang H, Cheng Z, Li X, Pang S, Zhang Y, et al. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial. Med. 2026. PMID: 41875890.
  6. 6.Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026. PMID: 42628555.
  7. 7.Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. PMID: 42419792.
  8. 8.Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, et al. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42410325.
  9. 9.Shirley M. Mazdutide: First Approval. Drugs. 2025. PMID: 41028652.
  10. 10.Innovent Biologics (Suzhou) Co. Ltd. A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2). NCT06164873. ClinicalTrials.gov. 2023. https://clinicaltrials.gov/study/NCT06164873
  11. 11.Innovent Biologics (Suzhou) Co. Ltd. Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg Administered Multiple Times in Chinese Patients With Moderate to Severe Obesity. NCT07000955. ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT07000955
  12. 12.Innovent Biologics (Suzhou) Co. Ltd. A Multicenter, Randomized, Open-label Phase III Study to Compare the Efficacy and Safety of IBI362 and Semaglutide in Chinese Overweight or Obese Subjects With Metabolic Dysfunction-associated Fatty Liver Disease (GLORY-3). NCT06884293. ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT06884293

Mazdutide (IBI362): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence

Mazdutide is a GLP-1/glucagon dual agonist approved in China in 2025 for weight management (not FDA-approved). What the phase 3 GLORY-1 trial showed: -14% body weight at 48 weeks on 6 mg, how it compares to semaglutide and tirzepatide, and what its approval means for US patients.

9 min read

SYNCHRONIZE-1: Survodutide Phase 3 Obesity Results Explained

Survodutide produced mean weight changes of -12.2% and -13.0% at 76 weeks versus -5.4% on placebo in its NEJM phase 3 trial. Here is what those numbers mean, why 16.6% also circulates, and what remains unknown.

8 min read

Survodutide for Fatty Liver: What the Phase 3 Nature Medicine Trial Shows

In the phase 3 SYNCHRONIZE-MASLD trial, survodutide 6.0 mg cut liver fat by at least 30% in 68.5% of adults at week 48, versus 28.6% on placebo. What that means, what the biopsy data add, and what the trial cannot show about scarring or liver outcomes.

8 min read

GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)

A tracker of next-generation GLP-1 and incretin drugs: retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide and the approved oral pill orforglipron (Foundayo), with stage and peak reported weight loss.

7 min read

What Is Mazdutide? The Obesity Drug Approved in China, Not the US

Mazdutide is a glucagon/GLP-1 dual agonist approved in China for weight management but unavailable in the US. What the approval authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad doesn't make a US-sold vial legitimate.

6 min read

Pemvidutide (Altimmune): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence

Pemvidutide is Altimmune's investigational GLP-1/glucagon dual agonist, not FDA-approved. The phase 2 MOMENTUM obesity topline (-15.6% at 48 weeks on 2.4 mg) and the phase 2b IMPACT MASH results, its body-composition signal, and how it compares to approved drugs.

9 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

Pricing Compare

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

Pricing Compare

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

Pricing Compare

Get started →